

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
10 July 2003 (10.07.2003)

PCT

(10) International Publication Number
WO 03/055479 A1(51) International Patent Classification⁷: A61K 31/38,
C07D 333/22, C07C 49/537, A61P 25/00PÉREZ MARTÍN, María, Concepción; Calle Santa Fe,
1 Izq., E-28008 Madrid (ES). MORENO MUÑOZ, Fran-
cisco, Jose; Calle Roble 1, 7 D, E-28036 Madrid (ES).
WANDOSELL JURADO, Francisco; Calle Cántaro 14,
E-28023 Madrid (ES).

(21) International Application Number: PCT/GB02/05768

(74) Agent: RUFFLES, Graham, Keith; Marks & Clerk,
57-60 Lincoln's Inn Fields, London WC2A 3LS (GB).(22) International Filing Date:
18 December 2002 (18.12.2002)

(25) Filing Language: English


(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC,
VN, YU, ZA, ZM, ZW.

(26) Publication Language: English

(30) Priority Data:

0130736.2 21 December 2001 (21.12.2001) GB
0201615.2 24 January 2002 (24.01.2002) GB(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK,
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).(71) Applicants: CONSEJO SUPERIOR DE INVESTI-
GACIONES CIENTÍFICAS [ES/ES]; Serrano, 113,
E-28006 Madrid (ES). UNIVERSIDAD AUTONOMA
DE MADRID (UAM) [ES/ES]; Carretera Colmenar, km
15, Cantoblanco, E-28049 Madrid (ES).**Published:**

— with international search report

(71) Applicant (for SD only): RUFFLES, Graham, Keith
[GB/GB]; 57-60 Lincoln's Inn Field, London WC2A 3LS
(GB).For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.(54) Title: COMPOUNDS AND THEIR THERAPEUTIC USE RELATED TO THE PHOSPHORYLATING ACTIVITY OF THE
ENZYME GSK-3(57) Abstract: Compounds of formula (I): wherein: X represents $\text{CH}=\text{CH}-$, $-\text{CH}=\text{CR}-$, $-\text{CR}=\text{CR}-$, $-\text{CO}-$, $-\text{O}-$, $-\text{NH}-$, $-\text{NR}-$, $-\text{S}-$, $-\text{SO}-$, $-\text{SO}_2-$, $-\text{CH}=\text{N}-$, $-\text{CR}=\text{N}-$, $-\text{CH}=\text{N}(\text{O})-$, $-\text{CR}=\text{N}(\text{O})-$ or any other atom or group of atoms capable of forming a 5- or 6- mem-
bered heterocyclic ring; γ^1 , γ^2 and γ^3 independently represent hydrogen or halogen; R^1 , R^2 and R^3 are independently represent
hydrogen, halogen, hydrocarbyl (-R), hydroxyl (-OH), hydrocarbyloxy (-O-R), mercapto (-SH), hydrocarbylthio (-S-R), hydrocar-
bylsulfinyl (-SO-R), hydrocarbylsulfonyl (-SO₂-R), nitro (-NO₂), amino (-NH₂), hydrocarbylamino (-NHR), bis(hydrocarbyl)amino
(-NR₂), hydrocarbylcarbonylamino (-NH-CO-R), cyano (-CN), carbamoyl (-CONH₂), hydrocarbylcarbamoyl (-CONHR), bis(hydro-
carbyl)carbamoyl (-CONR₂), carboxyl (-CO₂H), hydrocarbyloxycarbonyl (-CO₂R), formyl (-CHO), hydrocarbylcarbonyl (-COR),
hydrocarbylcarbonyloxy (-OCOR), optionally substituted heteroaryl or optionally substituted heterocyclic; and the hydrocarbyl
group R is a straight or branched chain hydrocarbyl group selected from alkyl, alkenyl, alkynyl, aryl, aralkyl, aralkenyl and ar-
alkynyl, which may optionally be substituted by one or more substituents, selected from those defined above in relation to R₁, R₂,
and R₃; are of use in the manufacture of a medicament for the treatment including prophylaxis of disease mediated by the activation
of GSK-3.

WO 03/055479 A1

COMPOUNDS AND THEIR THERAPEUTIC USE RELATED TO THE PHOSPHORYLATING ACTIVITY OF THE ENZYME GSK-3

TECHNICAL FIELD OF THE INVENTION

The present invention is enclosed within the pharmaceutical research and industry field. In particular, it is centred on the identification of previously described or new chemical compounds useful in the treatment of any pathology related to the phosphorylating activity of the enzyme GSK-3 as, for instance, Alzheimer's Disease, AD.

BACKGROUND OF THE INVENTION

The progressive ageing of the world population brings on the undesired consequence of an increase in the incidence of senile dementia. The most widely spread of this dementia is AD, which affects near 50% of the population aged 85 years or more and, as longevity increases, this rate will also increase unless the strategies to prevent or arrest the neurodegenerative processes become successful.

There are several biochemical processes affected in AD patients. The treatment of these pathologies would be a correct approach to diminish the damage caused by the disease but, up to now, the only drugs commercialised are some agents that improve cholinergic neurotransmission. Although temporarily, they alleviate the cognoscitive and memory failures associated to AD. At present, most of the research is mainly focused on the search of new agents useful in the treatment of two other pathologies, senile plaques and neurofibrillary tangles, which constitute the major histological lesions observed in AD brains and are also associated with the cholinergic neurotransmission

[“Modulation of β -amyloid precursor protein processing and tau phosphorylation by acetylcholine receptors” Hellström-Lindahl, E.; *Eur. J. Pharmacology* 2000, 393, 255-263].

The object of this invention is precisely related to the discovery of new products which are able to interfere the developing of neurofibrillary tangles. These tangles are formed by paired helical filaments whose main component is an intracellular, polar, quite hydrosoluble, microtubule-associated phosphoprotein protein named tau which appears abnormally phosphorylated. In normal cells, tau is essential for the integrity and stability of the neuronal cytoskeleton but its biological activity appears regulated by the degree of phosphorylation: normal brain tau contains 2-3 moles phosphate/mole protein while AD abnormally hyperphosphorylated tau contains 5-9 moles phosphate/mole protein [“Brain microtubule associated proteins: Modifications and disease” (Kosic, K. and Avila, J. Eds.) Chap. 7: “Tau phosphatases” Iqbal, K. *et al.* Harwood Academic Publishers, New York, pp. 95-111 (1997)]. Pathological tau presents a diminished capacity to stabilise microtubules, bringing on the corresponding neuronal degeneration, and aggregates into the filaments that form the tangles.


Hyperphosphorylation of tau and progress of AD relation is well demonstrated. Thus, selective inhibitors of the enzymes (kinases) that catalyse the abnormal phosphorylation of tau could become very useful therapeutic agents in the treatment of AD. In fact, the search for these inhibitors is an outstanding field of current pharmaceutical research [“Tau protein as a therapeutic target in Alzheimer’s disease and other neurodegenerative diseases” Larner, A. J.; *Expert Opinion on Therapeutic Patents* 1999, 9, 1359-1370].

Neither the whole tau hyperphosphorylation process nor all the kinases involved in it are completely known, but it is clear that GSK-3 is an *in vivo* kinase in brain and that it plays a central role in the pathological process. The discovery of non-toxic GSK-3 inhibitors would be very important, both from the scientific and industrial points of view, because, until now, the lithium cation is the only agent that have proved to inhibit GSK-3 but in therapeutically unacceptable high concentrations. A comprehensive review on this subject may be found in "Inhibition of tau phosphorylation: a new therapeutic strategy for the treatment of Alzheimer's disease and other neurodegenerative disorders" Castro, A.; Martínez, A.; *Expert Opinion on Therapeutic Patents* 2000, 10, 1519-1527. It has also been observed that insulin inactivates GSK-3 and that non-dependent insulin diabetes mellitus is related to the activation of the enzyme, so, there is the possibility that GSK-3 inhibitors could became new useful agents in the treatment of that kind of diabetes.

Research conducted by the present applicants has recently shown that a new family of aromatic and heteroaromatic ketones exhibit GSK-3 inhibitor activity at a micromolar or lower concentration level, thus leading to the completion of the present invention.

DESCRIPTION OF THE INVENTION

In a first aspect, the present invention provides compounds of general formula I:



wherein:

X represents $-\text{CH}=\text{CH}-$, $-\text{CH}=\text{CR}-$, $-\text{CR}=\text{CR}-$, $-\text{CO}-$, $-\text{O}-$, $-\text{NH}-$, $-\text{NR}-$, $-\text{S}-$, $-\text{SO}-$, $-\text{SO}_2-$, $-\text{CH}=\text{N}-$, $-\text{CR}=\text{N}-$, $-\text{CH}=\text{N}(\text{O})-$, $-\text{CR}=\text{N}(\text{O})-$ or any other atom or group of atoms capable of forming a 5- or 6-membered heterocyclic ring;

Y^1 , Y^2 and Y^3 independently represent hydrogen or halogen;

R^1 , R^2 and R^3 are independently represent hydrogen, halogen, hydrocarbyl

$(-\text{R})$, hydroxyl $(-\text{OH})$, hydrocarbyloxy $(-\text{O}-\text{R})$, mercapto $(-\text{SH})$, hydrocarbylthio $(-\text{S}-\text{R})$, hydrocarbylsulfinyl $(-\text{SO}-\text{R})$, hydrocarbylsulfonyl $(-\text{SO}_2-\text{R})$, nitro $(-\text{NO}_2)$, amino $(-\text{NH}_2)$, hydrocarbylamino $(-\text{NHR})$, bis(hydrocarbyl)amino $(-\text{NR}_2)$, hydrocarbylcarbonylamino $(-\text{NH}-\text{CO}-\text{R})$, cyano $(-\text{CN})$, carbamoyl $(-\text{CONH}_2)$, hydrocarbylcarbamoyl $(-\text{CONHR})$, bis(hydrocarbyl)carbamoyl $(-\text{CONR}_2)$, carboxyl $(-\text{CO}_2\text{H})$, hydrocarbyloxycarbonyl $(-\text{CO}_2\text{R})$, formyl $(-\text{CHO})$, hydrocarbylcarbonyl $(-\text{COR})$, hydrocarbylcarbonyloxy $(-\text{OCOR})$, optionally substituted heteroaryl or optionally substituted heterocyclic;

the hydrocarbyl group R is a straight or branched chain hydrocarbyl group selected from alkyl, alkenyl, alkynyl, aryl, aralkyl, aralkenyl and aralkynyl, which may optionally be substituted by one or more substituents, selected from those defined above in relation to R^1 , R^2 and R^3 .

As described below, the compounds of formula (I) are inhibitors of kinases in general and of GSK-3 in particular, and are therefore useful as possible therapeutic agents.

Therefore, in a second aspect, the invention provides the use of a compound of formula (I) as a medicament, in particular in the manufacture of a medicament for the treatment including prophylaxis of diseases mediated by the activation of GSK-3.

In a third aspect, the invention provides a method of treating a mammal, notably a human, affected by a disease mediated by the activation of GSK-3, which comprises administering to the affected individual a therapeutically effective amount of a compound of formula (I), or a pharmaceutical composition thereof.

In further aspects, the present invention provides a pharmaceutical preparation which contain as active ingredient a compound or compounds of the invention, as well as a process for the preparation of such a pharmaceutical.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

In the compounds of formula (I), the hydrocarbyl group R and the hydrocarbyl component of the other groups is a straight or branched chain hydrocarbyl group selected from alkyl, alkenyl, alkynyl, aryl, aralkyl, aralkenyl and aralkynyl. These are defined in more detail below.

In the definitions used in the present application, alkyl groups may be straight or branched chain groups and preferably have from 1 to about 12 carbon atoms, more preferably 1 to about 8 carbon atoms, still more

preferably 1 to about 6 carbon atoms, and most preferably 1, 2, 3 or 4 carbon atoms. Methyl, ethyl and propyl including isopropyl are particularly preferred alkyl groups in the compounds of the present invention. As used herein, the term alkyl, unless otherwise modified, refers to both cyclic and noncyclic groups, although cyclic groups will comprise at least three carbon ring members.

Preferred alkenyl and alkynyl groups in the compounds of the present invention have one or more unsaturated linkages and from 2 to about 12 carbon atoms, more preferably 2 to about 8 carbon atoms, still more preferably 2 to about 6 carbon atoms, even more prefereably 2, 3 or 4 carbon atoms. The terms alkenyl and alkynyl as used herein refer to both cyclic and noncyclic groups, although straight or branched noncyclic groups are generally more preferred.

The aryl groups in the compounds of the present invention preferably have 6 to 10 carbon atoms in a single aromatic carbocyclic ring or in two or more fused rings. Phenyl and naphthyl groups, especially the phenyl group, are preferred.

The aryl groups may optionally be substituted on the aromatic ring by one or more substituents. When more than one substituent is present, the substituents may be the same or different. The number of substituents on the aryl group is restricted only by the number of substitutable positions and by steric constraints. However, we prefer that the aryl groups have from 1 to 5, more preferably 1 to 3, still more preferably 1 or 2, and most preferably only 1 substituent. The substituents may include hydrocarbyl, hydroxyl, hydrocarbyloxy, mercapto, hydrocarbylthio, hydrocarbysulfinyl, hydrocarbysulfonyl, nitro, amino, hydrocarbylamino, bis(hydrocarbyl)amino, hydrocarbylcarbonylamino, cyano, carbamoyl, hydrocarbylcarbamoyl,

bis(hydrocarbyl)carbamoyl, carboxyl, hydrocarbyloxycarbonyl, formyl, hydrocarbylcarbonyl, hydrocarbylcarbonyloxy, optionally substituted heteroaryl or optionally substituted heterocyclic which are defined in more detail elsewhere in this specification.

Preferred aralkyl groups in the compounds of the present invention comprise an alkyl group having from 1 to 6 carbon atoms which is substituted with an aryl group as defined above to form an aralkyl group having a total of 7 to 16 carbon atoms. The aryl part of the aralkyl group may optionally be substituted on the aromatic ring by one or more substituents, the number and type of which is described above in relation to aryl groups. Examples of preferred aralkyl groups include benzyl, phenethyl, phenylpropyl, 1-naphthylmethyl and naphthylethyl, of which the benzyl group is most preferred.

Preferred aralkenyl and aralkynyl groups in the compounds of the present invention comprise an alkenyl or alkynyl group (preferably having 2 to 6 carbon atoms) which is substituted with an aryl group (as defined above) to form an aralkenyl or aralkynyl group having a total of 8 to 16 carbon atoms. Examples of preferred aralkyl groups include phenylethenyl (styryl) and phenylethynyl.

The hydrocarbyl groups in the compounds of the present invention may be substituted by a number of different groups, including hydrocarbyl, hydroxyl, hydrocarbyloxy, mercapto, hydrocarbylthio, hydrocarbylsulfinyl, hydrocarbylsulfonyl, nitro, amino, hydrocarbylamino, bis(hydrocarbyl)amino, hydrocarbylcarbonylamino, cyano, carbamoyl, hydrocarbylcarbamoyl, bis(hydrocarbyl)carbamoyl, carboxyl, hydrocarbyloxycarbonyl, formyl, hydrocarbylcarbonyl, hydrocarbylcarbonyloxy, optionally substituted heteroaryl or optionally substituted heterocyclic, which are defined in more detail elsewhere in

this specification. The number of substituents on the hydrocarbyl group is restricted only by the number of substitutable positions and by steric constraints. However, we prefer that the hydrocarbyl groups have from 1 to 5, more preferably 1 to 3, still more preferably 1 or 2, and most preferably only 1 substituent.

The definitions given above for the various types of hydrocarbyl groups in the compounds of the present invention also apply to the hydrocarbyl part of the other possible groups in these compounds. These are defined in more detail below for the preferred case wherein the hydrocarbyl group is an alkyl group.

Preferred alkoxy groups in the compounds of the present invention include groups having one or more (but preferably only one) oxygen linkages and from 1 to about 12 carbon atoms, more preferably from 1 to about 8 carbon atoms, and still more preferably 1 to about 6 carbon atoms, and most preferably 1, 2, 3 or 4 carbon atoms.

Preferred alkylthio groups in the compounds of the present invention have one or more (but preferably only one) thioether linkages and from 1 to about 12 carbon atoms, more preferably from 1 to about 8 carbon atoms, and still more preferably 1 to about 6 carbon atoms. Alkylthio groups having 1, 2, 3 or 4 carbon atoms are particularly preferred.

Preferred alkylsulfinyl groups in the compounds of the present invention include those groups having one or more sulfoxide (SO) groups and from 1 to about 12 carbon atoms, more preferably from 1 to about 8 carbon atoms, and still more preferably 1 to about 6 carbon atoms. Alkylsulfinyl groups having 1, 2, 3 or 4 carbon atoms are particularly preferred.

Preferred alkylsulfonyl groups in the compounds of the present invention include those groups having one or more sulfonyl (SO_2) groups and from 1 to about 12 carbon atoms, more preferably from 1 to about 8 carbon atoms, and still more preferably 1 to about 6 carbon atoms. Alkylsulfonyl groups having 1, 2, 3 or 4 carbon atoms are particularly preferred.

The halogen atoms in the compounds of the present invention are preferably fluorine, chlorine, bromine or iodine, of which chlorine and bromine are more preferred.

Preferred alkylcarbonyl (alkanoyl) groups in the compounds of the present invention include those groups having one or more carbonyl (CO) groups and from 1 to about 30 carbon atoms, more preferably from 1 to about 12 carbon atoms, and still more preferably 1 to about 6 carbon atoms (including the carbonyl carbon). Alkanoyl groups having 1, 2, 3 or 4 carbon atoms, especially the formyl, acetyl, propionyl, butyryl and isobutyryl groups, are preferred and the acetyl group is especially preferred.

The alkanoyl group may be substituted with one or more (but preferably only one) substituents, which may preferably be selected from halogen, hydroxy, alkoxy and cyano, especially a halogen atom, particularly chlorine or bromine.

Preferred alkylcarbonyloxy (alkanoyloxy) groups in the compounds of the present invention include those groups having one or more carbonyloxy groups and from 1 to about 30 carbon atoms, more preferably from 1 to about 12 carbon atoms, and still more preferably 1 to about 6 carbon atoms (including the carbonyl carbon). When the term "alkanoyloxy" is used, it is to be understood that the group is

attached to the rest of the molecule via the oxygen atom. Alkanoyloxy groups having 1, 2, 3 or 4 carbon atoms, especially the formyloxy, acetoxy, propionyloxy, butyryloxy and isobutyryloxy groups, are preferred and the formyloxy and acetoxy groups especially preferred.

Preferred alkylcarbonylamino (alkanoylamino) groups in the compounds of the present invention include those groups having an -NH-CO-linkage (the group being attached to the rest of the molecule via the nitrogen atom) and from 1 to about 30 carbon atoms, more preferably from 1 to about 12 carbon atoms, and still more preferably 1 to about 6 carbon atoms (including the carbonyl carbon). the group is attached to the rest of the molecule via the nitrogen atom. Alkanoylamino groups having 1, 2, 3 or 4 carbon atoms, especially the formylamino, acetylamino, propionylamino, butyrylamino and isobutyrylamino groups, are preferred and the formylamino and acetylamino groups especially preferred.

Preferred N-alkylcarbamoyl groups in the compounds of the present invention comprise a -CO-NH- linkage (the group being attached to the rest of the molecule via the carbonyl carbon) wherein the nitrogen atom is substituted with an alkyl group having from 1 to about 12 carbon atoms, more preferably 1 to about 6 carbon atoms. N-Alkylcarbamoyl groups having 1, 2, 3 or 4 carbon atoms, especially the N-methylcarbamoyl, N-ethylcarbamoyl, N-propylcarbamoyl and N-butylcarbamoyl groups, are particularly preferred.

Preferred dialkylcarbamoyl groups in the compounds of the present invention comprise a -CO-N- linkage (the group being attached to the rest of the molecule via the carbonyl carbon) wherein the nitrogen atom is substituted with two alkyl groups, each having from 1 to about 12 carbon atoms, more preferably 1 to about 6 carbon atoms. The alkyl

groups may be the same or different. N,N-Dialkylcarbamoyl groups wherein each alkyl group has 1, 2, 3 or 4 carbon atoms, especially the N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, N-ethyl-N-propylcarbamoyl, N,N-dipropylcarbamoyl, N,N-dibutylcarbamoyl and N-methyl-N-butylcarbamoyl groups, are particularly preferred.

Preferred monoalkylamino groups in the compounds of the present invention have one or more (but preferably only one) NH linkages and from 1 to about 12 carbon atoms, more preferably from 1 to about 8 carbon atoms, and still more preferably 1 to about 6 carbon atoms. Alkylamino groups having 1, 2, 3 or 4 carbon atoms, especially the methylamino, ethylamino, propylamino and butylamino groups, are particularly preferred.

Preferred dialkylamino groups in the compounds of the present invention have one or more (but preferably only one) nitrogen atom bonded to two alkyl groups, each of which may from 1 to about 12 carbon atoms, more preferably from 1 to about 8 carbon atoms, and still more preferably 1 to about 6 carbon atoms. The alkyl groups may be the same or different. Dialkylamino groups wherein each alkyl group has 1, 2, 3 or 4 carbon atoms, especially the dimethylamino, diethylamino, N-methylethylamino, N-ethylpropylamino, dipropylamino, dibutylamino and N-methylbutylamino groups, are particularly preferred.

Preferred alkoxy carbonyl groups in the compounds of the present invention include those groups having one or more (but preferably only one) oxycarbonyl groups and from 1 to about 30 carbon atoms, more preferably from 1 to about 12 carbon atoms, and still more preferably 1 to about 6 carbon atoms (including the carbonyl carbon). When the

term "alkoxycarbonyl" is used, it is to be understood that the group is attached to the rest of the molecule via the carbonyl carbon.

Alkoxycarbonyl groups having 1, 2, 3 or 4 carbon atoms, especially the methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl and butoxycarbonyl are preferred and the methoxycarbonyl and ethoxycarbonyl groups especially preferred.

Heteroaromatic groups in the compounds of the present invention preferably have from 5 to 14 ring atoms in a single aromatic ring or in 2 or more fused rings. At least one of the ring atoms (preferably from 1 to 4 ring atoms, more preferably 1 to 3 ring atoms, even more preferably 1 or 2 ring atoms, and most preferably 1 ring atom) is a heteroatom, which is preferably selected from nitrogen, oxygen and sulfur atoms. The heteroaromatic group may optionally be fused to another heteroaromatic group or to an aryl group, examples of which are defined above. Examples of preferable heteroaromatic groups include pyridyl, furyl, thienyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, tetrazolyl, pyranyl, pyridyl, pyrimidinyl, pyridazinyl, indolyl, benzimidazolyl, benzofuryl, benzothienyl and benzisoxazolyl.

The heteroaromatic groups in the compounds of the present invention may be substituted by a number of different groups, including hydrocarbyl, hydroxyl, hydrocarbyloxy, mercapto, hydrocarbylthio, hydrocarbylsulfinyl, hydrocarbylsulfonyl, nitro, amino, hydrocarbylamino, bis(hydrocarbyl)amino, hydrocarbylcarbonylamino, cyano, carbamoyl, hydrocarbylcarbamoyl, bis(hydrocarbyl)carbamoyl, carboxyl, hydrocarbyloxycarbonyl, formyl, hydrocarbylcarbonyl, hydrocarbylcarbonyloxy, optionally substituted heteroaryl or optionally substituted heterocyclic, which are defined in more detail elsewhere in this specification. The number of substituents on the heteroaromatic group is restricted only by the number of substitutable positions and by

steric constraints. However, we prefer that the heteroaromatic groups have from 1 to 5, more preferably 1 to 3, still more preferably 1 or 2, and most preferably only 1 substituent.

The heterocyclic groups (other than the heteroaromatic groups defined above) in the compounds of the present invention preferably contain from 3 to 14 ring atoms in a single ring or 2 or more fused rings. At least one of the ring atoms (preferably from 1 to 4 ring atoms, more preferably 1 to 3 ring atoms, even more preferably 1 or 2 ring atoms, and most preferably 1 ring atom) is a heteroatom, which is preferably selected from nitrogen, oxygen and sulfur atoms. The heterocyclic group may optionally be fused to a cycloalkyl group, a heterocyclic group, an aryl group or a heteroaromatic groups, examples of which are defined above. Preferred heterocyclic groups include azetidinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothiofuranyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, chromanyl and thiochromanyl.

The heterocyclic groups in the compounds of the present invention may be substituted by a number of different groups, including hydrocarbyl, hydroxyl, hydrocarbyloxy, mercapto, hydrocarbylthio, hydrocarbylsulfinyl, hydrocarbylsulfonyl, nitro, amino, hydrocarbylamino, bis(hydrocarbyl)amino, hydrocarbylcarbonylamino, cyano, carbamoyl, hydrocarbylcarbamoyl, bis(hydrocarbyl)carbamoyl, carboxyl, hydrocarbyloxycarbonyl, formyl, hydrocarbylcarbonyl, hydrocarbylcarbonyloxy, optionally substituted heteroaryl or optionally substituted heterocyclic, which are defined in more detail elsewhere in this specification. The number of substituents on the heterocyclic group is restricted only by the number of substitutable positions and by steric constraints. However, we prefer that the heterocyclic groups

have from 1 to 5, more preferably 1 to 3, still more preferably 1 or 2, and most preferably only 1 substituent.

Preferably X is selected from $-\text{CH}=\text{CH}-$, $-\text{CH}=\text{CR}-$, $-\text{CR}=\text{CR}-$, $-\text{CH}=\text{N}-$, $-\text{CR}=\text{N}-$, $-\text{O}-$, $-\text{NH}-$, $-\text{NR}-$, and $-\text{S}-$ (the group R representing C_{1-6} alkyl or C_{6-10} aryl).

More preferably, X is selected from $-\text{CH}=\text{CH}-$, $-\text{CH}=\text{CR}-$, $-\text{CR}=\text{CR}-$, $-\text{O}-$ and $-\text{S}-$ (the group R representing C_{1-6} alkyl).

Most preferably, X is selected from $-\text{CH}=\text{CH}-$ and $-\text{S}-$.

Preferably, one or two of Y^1 , Y^2 and Y^3 are halogen, and the other two or one are hydrogen.

More preferably, one of Y^1 , Y^2 and Y^3 is halogen, and the other two are hydrogen.

Most preferably, one of Y^1 , Y^2 and Y^3 is chlorine or bromine, and the other two are hydrogen.

Iodo is also a preferred possibility for one of the Y groups, with the other two being hydrogen.

Preferably, R^1 , R^2 and R^3 are independently selected from hydrogen, halogen, C_{1-6} alkyl (which may be optionally substituted with one or more substituents selected from halogen, hydroxy, C_{1-6} alkoxy and cyano), C_{6-10} aryl, optionally substituted C_{7-16} aralkyl, hydroxy, C_{1-6} alkoxy, C_{6-10} aryloxy, C_{7-16} aralkyloxy, C_{1-6} alkylthio, C_{6-10} arylthio, C_{7-16} aralkylthio, C_{1-6} alkylsulfinyl, C_{6-10} arylsulfinyl, C_{7-16} aralkylsulfinyl, C_{1-6} alkylsulfonyl, C_{6-10} arylsulfonyl, C_{7-16} aralkylsulfonyl, cyano, carboxyl,

C_{1-6} alkyloxycarbonyl, C_{7-11} aryloxycarbonyl, C_{8-16} aralkyloxycarbonyl, heteroaryl and C_{1-30} aliphatic acyl (which may be optionally substituted with one or more substituents selected from halogen, hydroxy and C_{1-6} alkoxy and cyano)).

More preferably, R^1 , R^2 and R^3 are independently selected from hydrogen, halogen, C_{1-6} alkyl (which may be optionally substituted with one or more substituents selected from halogen, hydroxy and C_{1-6} alkoxy), C_{1-6} alkoxy, C_{6-10} aryl, heteroaryl, nitro, amino and C_{1-20} aliphatic acyl (which may be optionally substituted with one or more substituents selected from halogen, hydroxy and C_{1-6} alkoxy and cyano).

Still more preferably, R^1 , R^2 and R^3 are independently selected from hydrogen, halogen, C_{1-4} alkyl (which may be optionally substituted with one or more halogen atoms), C_{1-4} alkoxy, C_{6-10} aryl, heteroaryl, nitro, amino and C_{2-6} aliphatic acyl (which may be optionally substituted with one or more halogen atoms), provided that at least one of R^1 , R^2 and R^3 are other than hydrogen.

Yet more preferably, R^1 , R^2 and R^3 are independently selected from hydrogen, chlorine, bromine, methyl, ethyl, methoxy, ethoxy, acetyl, chloroacetyl, phenyl, morpholino, nitro, amino and bromoacetyl, provided that at least one of R^1 , R^2 and R^3 is other than hydrogen.

Even more preferably, R^1 , R^2 and R^3 are independently selected from hydrogen, chlorine, bromine, methyl, methoxy, phenyl, morpholino, nitro, amino and chloroacetyl, provided that at least one of R^1 , R^2 and R^3 is other than hydrogen.

As the person skilled in the art will readily appreciate, the preferred definitions of X, Y¹, Y², Y³, R¹, R², and R³ may be combined in various ways, and the compounds covered by all such combinations and permutations of the above preferred definitions are to be considered as being part of this invention. More especially, we prefer compounds wherein -X- is -S- or -CH=CH-; is bromo-, dibromo-, chloro-, dichloro- or iodo- acetyl; R¹ is one of the possibilities listed in Table 1 for R¹, R² or R³; R² is one of the possibilities listed in Table 1 for R¹, R² or R³; and R³ is one of the possibilities listed in Table 1 for R¹, R² or R³.

Preferred compounds of formula (I) are selected from the following Table 1.




Table 1

comp.	-X-	CO-CY ¹ Y ² Y ³	R ¹	R ²	R ³
1	-S-	3-COCH ₂ Cl	2-Br	4-Cl	5-Cl
2	-S-	2-COCH ₂ Cl	4-Cl	5-Cl	H
3	-S-	2-COCH ₂ Cl	4-Br	H	H
4	-S-	3-COCH ₂ Cl	4-Cl	H	H
5	-S-	3-COCH ₂ Cl	2-Br	4-Br	5-Br
6	-S-	3-COCH ₂ Cl	2-Cl	5-Cl	H
7	-S-	2-COCH ₂ Cl	5-Cl	H	H
8	-S-	2-COCH ₂ Cl	5-Br	H	H
9	-S-	2-COCH ₂ Cl	4-COCH ₂ Cl	H	H
10	-S-	2-COCH ₂ Cl	H	H	H
11	-S-	2-COCH ₂ Cl	4-COCH ₂ Cl	5-CH ₃	H

12	-S-	2-COCH ₂ Cl	5-CH ₃	H	H
13	-S-	3-COCH ₂ Cl	2-CH ₃	5-CH ₃	H
14	-S-	2-COCH ₂ Cl	4-Br	5-Br	H
15	-S-	2-COCH ₂ Cl	3-Br	4-Br	H
16	-S-	2-COCH ₂ Cl	3-CH ₃	4-COCH ₂ Cl	H
17	-S-	2-COCH ₂ Cl	4-CH ₃	H	H
18	-S-	2-COCH ₂ Cl	3-CH ₃	H	H
19	-S-	2-COCH ₂ Cl	5-COCH ₃	H	H
20	-S-	2-COCH ₂ Cl	4-COCH ₃	H	H
21	-S-	2-COCH ₂ Br	3-Br	4-Br	H
22	-S-	2-COCH ₂ Br	4-Br	5-Br	H
23	-S-	2-COCH ₂ Br	5-Br	H	H
24	-CH=CH-	COCH ₂ Cl	4-Cl	H	H
25	-CH=CH-	COCH ₂ Cl	H	H	H
26	-CH=CH-	COCH ₂ Br	2-Br	4-Br	6-Br
27	-CH=CH-	COCH ₂ Br	3-Br	4-Br	H
28	-CH=CH-	COCH ₂ Br	4-Br	H	H
29	-CH=CH-	COCH ₂ Br	4-Cl	H	H
30	-CH=CH-	COCH ₂ Br	H	H	H
31	-CH=CH-	COCH ₂ Br	4-CH ₃	H	H
32	-CH=CH-	COCH ₂ Br	4-OCH ₃	H	H
33	-CH=CH-	COCH ₂ Br	4-Ph	H	H
34	-CH=CH-	COCHBrCl	4-Cl	H	H
35	-CH=CH-	COCHBrCl	H	H	H
36	-CH=CH-	COCHBr ₂	H	H	H
37	-CH=CH-	COCHBr ₂	4-Br	H	H
38	-CH=CH-	COCH ₂ Br	4-CN	H	H
39	-CH=CH-	COCHBr ₂	4-CN	H	H
40	-CH=CH-	COCH ₂ Br	4-CF ₃	H	H
41	-CH=CH-	COCHBr ₂	4-CF ₃	H	H

42	-CH=CH-	COCH ₂ Br	4-Morpholine	H	H
43	-CH=CH-	COCH ₂ Br	3-CN	H	H
44	-CH=CH-	COCHBr ₂	3-CN	H	H
45	-CH=CH-	COCHBr ₂	4-I	H	H
46	-CH=CH-	COCH ₂ Br	4-NO ₂	H	H
47	-CH=CH-	COCH ₂ Br	3-Br	4-NH ₂	5-Br
48	-CH=CH-	COCH ₂ I	4-Br	H	H


In further aspects, the present invention provides a pharmaceutical preparation, which contains as active ingredient a compound or compounds of the invention, as well as a process for its preparation.

Examples of pharmaceutical compositions include any solid (tablets; pills, capsules, granules, etc.) or liquid (solutions, suspensions or emulsions) with suitable composition or oral, topical or parenteral administration, and they may contain the pure compound or in combination with any carrier or other pharmacologically active compounds. These compositions may need to be sterile when administered parenterally.

Synthesis of the compounds of the invention


Most of the compounds whose biological activity is the object of the present invention can be synthesised following a general procedure previously described [Conde, S.; Corral, C.; Madroñero, R.; Sánchez Alvarez-Insúa, A.; Fernández-Tomé M. P.; del Río. J.; *J. Med. Chem.* 1977, 20, 970-974]. Following this synthetic method, an aromatic or heteroaromatic compound of formula II reacts with a mixture of a substituted acetyl halide of formula III, e. g. chloroacetyl chloride, bromoacetyl bromide, etc, and a Lewis acids, such as TiCl₄, SnCl₄, AlCl₃, etc, in an aprotic anhydrous organic solvent, for example, CS₂,

CCl₄, etc. This process is represented in Scheme 1, where Y' represents a halogen atom (F, Cl, Br or I).



Scheme 1

Another group of compounds can be synthesised by the general synthetic procedure of halogenation [described, for example, in: Seeger, D. E.; Lahti, P. M.; Rossi, A. R.; Benson, J. A.; *J. Am. Chem. Soc.* 1986, 108, 1251-1265] represented in Scheme 2. Following this procedure, an aromatic or heteroaromatic ketone IV is treated with the desired halogen in the medium of a polar organic solvent, such as acetic acid, dioxane, etc, to obtain the α -halomethyl ketone V, which falls within the scope of compounds of formula I but has a single halogen atom Y.



Scheme 2

Activity of the compounds of the invention

In the following examples, the selective enzyme GSK-3 inhibition by the compounds of the invention is demonstrated. As described above, it has been established that the enzyme GSK-3 plays a crucial role in the ethiopathogenia of AD as responsible of the hyperphosphorylation of the protein tau observed in this pathology. Because of the biological

activity of these products as GSK-3 inhibitors, they can be considered as important prototypes or lead compounds of a new family of compounds that can prevent the formation of neurofibrillary tangles and reverse those already formed.

The compounds of the invention are capable of inhibiting the enzyme GSK-3. The compounds of the invention are therefore useful as therapeutical agents in the treatment of neurodegenerative diseases, such as AD or any other associated to the pathology of protein tau, or to the activation of GSK-3, such as non-insulin dependent diabetes mellitus.

In addition, due to their ability to inhibit the cellular cycle, the compounds of the invention are also useful in the treatment of hyperproliferative diseases, for example, displasias and metaplasias of different tissues, psoriasis, arteriosclerosis and cancer. Their application in the treatment of these pathologies forms also part of the present invention.

WO 9640982 provides compositions for therapy of neurodegenerative disease comprising an efficacious amount of a selective PLA₂ inhibitor. p-Bromophenacyl bromide is given as an example of such a selective PLA₂ inhibitor. The present invention disclaims this use of p-bromophenacyl bromide. In preferred compounds of this invention, a phenacyl bromide is not substituted with one substituent which is p-bromo, or a p-bromoacetophenone compound does not have one substituent which is α -bromo, or the compound is not a selective PLA₂ inhibitor.

EXAMPLES

Synthesis of some of the compounds of the invention

Examples 1 and 2: 1-(2-Bromo-4,5-dichloro-thiophen-3-yl)-2-chloro-ethanone (1) and 2-Chloro-1-(4,5-dichloro-thiophen-2-yl)-ethanone (2) (general procedure).

Chloroacetyl chloride (4.60 ml, 0.058 mol) was added to a stirred suspension of aluminium trichloride (7.70 g, 0.058 mol) in carbon disulphide (50 ml) placed in a 250 ml round-bottom flask equipped with a reflux condenser, an addition funnel and a magnetic stirring bar. The mixture was stirred at room temperature overnight and then refluxed for 1h. Afterwards, the reaction was ice-cooled and treated with 1N aqueous HCl (50 ml). The organic layer was separated, washed with water, dried over magnesium sulphate and the solvent evaporated. The residue yielded two compounds by chromatography column (hexane:ethyl acetate 10:1): the compound **1** (9.72g, 63%) [m.p.:85-86 °C (heptane), ¹H-NMR (CDCl₃): δ = 4.68 (s, CH₂Cl)] and a second compound (**2**) identified as 2-chloroacetyl-4,5-dichlorothiophene (2.53g, 22%), previously described [del Agua *et al* *J. Heterocyclic Chem.* **1981**, 18,1345-1347].

Example 3: 1-(4-Bromo-thiophen-2-yl)-2-chloro-ethanone

This compound was previously described by Conde *et al* [*J. Med. Chem.* **1977**, *20*, 970-974].

Example 4: 2-Chloro-1-(4-chloro-thiophen-3-yl)-ethanone

This compound was previously described by Conde *et al* [*J. Med. Chem.* **1977**, *20*, 970-974].

Example 5: 2-Chloro-1-(2,4,5-tribromo-thiophen-3-yl)-ethanone.

This compound was previously described by del Agua *et al* [*J. Heterocyclic Chem.* **1981**, *18*, 1345-1347].

Example 6: 2-Chloro-1-(2,5-dichloro-thiophen-3-yl)-ethanone.

General procedure described for compounds **1** and **2** starting from 2,5-dichlorothiophene and chloroacetyl chloride. Purified by column chromatography column (hexane:ethyl acetate 12:1), yield 91%, m.p.: 43-44°C (ethanol), ¹H-NMR (CDCl₃): δ 7.1 (s, 1H, CH-Aromat), 4.6 (s, 2H, CH₂); ¹³C-NMR (CDCl₃) : 186.6 (CO), 136.9 (C-Cl), 136.0 (C-CO), 130.2 (C-Cl), 129.4 (CH-Ar), 50.6 (CH₂); M/z (EI): 234, 232, 230, 228 (M⁺, 1, 6, 16, 16 %), 183, 181, 179 (M-CH₂Cl, 18, 79, 100 %), 155, 153, 151 (M-COCH₂Cl, 3, 13, 19 %), 118, 116 (M-COCH₂Cl₂, 5, 13 %); HPLC: Delta Pak Column C18, 5 μm, 300 A, (150 X 3.9 mm), Purity 99 %, r.t.= 6.16 min, acetonitrile / H₂O (0.05 % H₃PO₄ + 0.04 % Et₃N) 50/50.

Example 7: 2-Chloro-1-(5-chloro-thiophen-2-yl)-ethanone

This compound was previously described by Emerson *et al.* [*J. Org. Chem.* **1948**, *13*, 729-730].

Example 8: 1-(5-Bromo-thiophen-2-yl)-2-chloro-ethanone.

This compound was previously described by del Agua *et al* [*J. Heterocyclic Chem.* **1981**, *18*, 1345-1347].

Examples 9 and 10: 2-Chloro-1-[4-(2-chloro-acetyl)-thiophen-2-yl]-ethanone (9) and 2-Chloro-1-thiophen-2-yl-ethanone (10)

General procedure described for compounds **1** and **2** starting from thiophene and chloroacetyl chloride. Two products were isolated by column chromatography column (hexane:ethyl acetate 4:1).

Compound **9**: yield 68%, m.p.: 154-155 °C (water/methanol), ¹H-NMR (CDCl₃): δ 8.4 (s, 1H, H₅), 8.2 (s, 1H, H₃), 4.6 (s, 2H, CH₂), 4.5 (s, 2H, CH₂); ¹³C-NMR (CDCl₃): δ 189.0 (CO), 188.2 (CO), 145.9 (C-CO), 144.3 (CH), 143.3 (C-CO), 135.9(CH), 49.7 (CH₂), 49.1 (CH₂); M/z (EI): 240, 238, 236 (M⁺, 1, 2, 8 %), 189, 187 (M-CH₂Cl, 39, 100 %); HPLC: Delta Pak Column C18, 5 μm, 300 A, (150 X 3.9 mm), Purity 96 %, r.t.= 3.21 min, acetonitrile / H₂O (0.05 % H₃PO₄ + 0.04 % Et₃N)]50/50.

Compound **10** (13%) was previously described by Nakayama, J. *et al* [Heterocycles . **1987**, 26, 10, 2599-2602].

Examples 11 and 12: 2-Chloro-1-[4-(2-chloro-acetyl)-5-methyl-thiophen-2-yl]-ethanone (11) and 2-Chloro-1-(5-methyl-thiophen-2-yl)-ethanone (12)

General procedure described for compounds **1** and **2** starting from 2-methylthiophene and chloroacetyl chloride. Two products were isolated by column chromatography column (hexane:ethyl acetate 6:1).

Compound **11**: yield 73%, m.p.: 110-111 °C (hexane), ¹H-NMR (CDCl₃): δ 8.0 (s, 1H, Ar), 4.54 (s, 2H, CH₂), 4.52 (s, 2H, CH₂), 2.8 (s, 3H, CH₃); ¹³C-NMR (CDCl₃): δ 190.3 (CO), 187.7 (CO), 164.6 (C-CH₃), 140.3 (C-CO), 137.4 (C-CO), 137.1 (CH), 51.2 (CH₂), 48.9 (CH₂), 21.1 (CH₃); M/z (EI): 254, 252, 250 (M⁺, 2, 11, 15 %), 203, 201 (M-CH₂Cl, 52, 100 %); HPLC: Delta Pak Column C18, 5 μm, 300 A, (150 X 3.9 mm), Purity 94 %, r.t.= 3.89 min, acetonitrile / H₂O (0.05 % H₃PO₄ + 0.04 % Et₃N) 50/50. Compound **12** (8%), was previously described by Belenkii *et al* [J. Org. Chem. **1970**, 6, 2531-2534].

Example 13: 2-Chloro-1-(2,5 dimethyl-thiophen-3-yl)-ethanone.

This compound was previously described by Belenkii *et al* [*J. Org. Chem.* **1970**, *6*, 2531-2534].

Example 14: 2-Chloro-1-(4,5-dibromo-thiophen-2-yl)-ethanone.

This compound was previously described by del Agua *et al* [*J. Heterocyclic Chem.* **1981**, *18*, 1345-1347].

Example 15: 2-Chloro-1-(3,4-dibromo-thiophen-2-yl)-ethanone.

General procedure described for compounds **1** and **2** starting from 3,4-dibromothiophene and chloroacetyl chloride. The product was isolated by column chromatography column (hexane:ethyl acetate 8:1). Yield 97%, m.p.: 86-87 °C , ¹H-NMR (CDCl₃): δ 7.7 (s, 1H, Ar), 4.8 (s, 2H, CH₂); ¹³C-NMR (CDCl₃): δ 185.4 (CO), 140.0 (C-CO), 133.7 (CH), 120.8 (C-Br), 119.6 (C-Br), 50.1 (CH₂); M/z (EI): 322, 320, 318, 316 (M⁺, 3, 11, 15, 7 %), 271, 269, 267 (M-CH₂Cl, 56, 100, 56 %); HPLC: Delta Pak Column C18, 5 μm, 300 A, (150 X 3.9 mm), Purity 94 %, r.t.= 6.06 min, acetonitrile / H₂O (0.05 % H₃PO₄ + 0.04 % Et₃N) 50/50.

Examples 16, 17 and 18: 2-Chloro-1-[5-(2-chloro-acetyl)-4-methyl-thiophen-3-yl]-ethanone (**16**), 2-Chloro-1-(4-methyl-thiophen-2-yl)-ethanone (**17**) and 2-chloro-1-(3-methyl-thiophen-2-yl)-ethanone (**18**)

General procedure described for compounds **1** and **2** starting from 3-methylthiophene and chloroacetyl chloride. Three products were isolated by column chromatography column (hexane:ethyl acetate 3:1). Compound 16: yield 69%, m.p.: 155-156 °C , ¹H-NMR (CDCl₃): δ 8.2 (s, 1H, Ar), 4.54 (s, 2H, CH₂), 4.52 (s, 2H, CH₂), 2.8 (s, 3H, CH₃); ¹³C-NMR

(CDCl₃): δ 187.2 (CO), 185.1 (CO), 148.2 (C-CO), 139.1 (C-CO), 137.9 (CH), 48.1 (CH₂), 47.3 (CH₂), 16.0 (CH₃); M/z (EI): 254, 252, 250 (M⁺, 1, 6, 9 %), 203, 201 (M-CH₂Cl, 47, 100 %); HPLC: Column μ Bondapack C18, 5 μm, 300 A, (300 X 3.9 mm), Purity 99 %, r.t.= 4.73min, acetonitrile / H₂O (0.05 % H₃PO₄ + 0.04 % Et₃N) 50/50. Compound **17**: yield 8%, m.p.; 76-77 °C, ¹H-NMR (CDCl₃): δ 7.6 (s, 1H, Ar), 7.1 (s, 1H, Ar), 4.55 (s, 2H, CH₂), 2.3 (s, 3H, CH₃); ¹³C-NMR (CDCl₃): δ 188.1 (CO), 144.2 (C-CO), 143.2 (C-CH₃), 138.9 (CH), 134.9 (CH), 49.4 (CH₂), 19.5 (CH₃); M/z (EI): 176, 174 (M⁺, 9, 23 %), 125 (M-CH₂Cl, 100 %); HPLC: Column μ Bondapack C18, 5 μm, 300 A, (300 X 3.9 mm), Purity 98 %, r.t.= 4.56 min, Conditions Acetonitrile / H₂O [(0.05 % H₃PO₄ + 0.04 % Et₃N)] 50/50. Compound **18** yield 5%, yellow oil, ¹H-NMR (CDCl₃): δ 7.44 (d, J= 4.9 Hz, 1H, Ar), 7.0 (d, J= 4.9 Hz, 1H, Ar), 4.55 (s, 2H, CH₂), 2.3 (s, 3H, CH₃); ¹³C-NMR (CDCl₃): δ 188.2 (CO), 151.3 (C-CH₃), 136.8 (CH), 136.2 (C-CO), 135.0 (CH), 51.5 (CH₂), 20.9 (CH₃); M/z (EI): 176, 174 (M⁺, 6, 16 %), 125 (M-CH₂Cl, 100 %); HPLC: Column μ Bondapack C18, 5 μm, 300 A, (300 X 3.9 mm), Purity 99 %, r.t.= 3.65 min, acetonitrile / H₂O (0.05 % H₃PO₄ + 0.04 % Et₃N) 50/50.

Example 19: 1-(5-Acetyl-thiophen-2-yl)-2-chloro-ethanone.

General procedure described for compounds **1** and **2** starting from 2-acetylthiophene and chloroacetyl chloride. Purified by column chromatography column (hexane:ethyl acetate 3:1), yield 25%, m.p.: 94 - 95°C, ¹H-NMR (CDCl₃): δ 8.3 (d, J= 4.2 Hz, 1H, Ar), 8.1 (d, J=4.2 Hz, 1H, Ar), 4.55 (s, 2H, CH₂), 2.6 (s, 3H, CH₃); ¹³C-NMR (CDCl₃): δ 193.0 (CO), 187.8 (CO), 148.3 (C-CO), 142.0 (CH), 141.7 (C-CO), 133.7 (CH), 48.3 (CH₂), 29.2 (CH₃); M/z (EI): 204, 202 (M⁺, 4, 10 %), 153 (M-CH₂Cl, 100 %); HPLC: Column μ Bondapack C18, 5 μm, 300 A, (300 X 3.9 mm), Purity 98 %, r.t.= 3.50 min, acetonitrile / H₂O (0.05 % H₃PO₄ + 0.04 % Et₃N) 50/50.

Example 20: 1-(4-Acetyl-thiophen-2-yl)-2-chloro-ethanone.

General procedure described for compounds **1** and **2** starting from 3-acetylthiophene and chloroacetyl chloride. Purified by column chromatography column (hexane:ethyl acetate 2:1), yield 41% m.p.: 118-119 °C, ¹H-NMR (CDCl₃): δ 8.3 (s, 1H, Ar), 8.1 (s, 1H, Ar), 4.60 (s, 2H, CH₂), 2.56 (s, 3H, CH₃); ¹³C-NMR (CDCl₃): δ 191.6 (CO), 184.5 (CO), 143.3 (C-CO), 141.7 (C-CO), 139.7 (CH), 132.0 (CH), 45.4 (CH₂), 27.4 (CH₃); M/z (EI): 204, 202 (M⁺, 6, 17 %), 153 (M-CH₂Cl, 100 %); HPLC: Delta Pak Column C18, 5 μm, 300 A, (150 X 3.9 mm), Purity 94 %, r.t.= 2.70 min, acetonitrile / H₂O (0.05 % H₃PO₄ + 0.04 % Et₃N) 50/50.

Example 21: 2-Bromo-1-(3,4-dibromo-thiophen-2-yl)-ethanone.

This compound was previously described by Bagli *et al* [Can. J. Chem. **1975**, 53, 2598].

Example 22: 2-Bromo-1-(4,5-dibromo-thiophen-2-yl)-ethanone.

This compound was previously described by Bagli *et al* [Can. J. Chem. **1975**, 53, 2598].

Example 23: 2-Bromo-1-(5-bromo-thiophen-2-yl)-ethanone.

This compound was previously described by Raeymaekers *et al*. [J. Med. Chem. **1966**, 9, 545-551].

Example 24: 2-Chloro-1-(4-chloro-phenyl)-ethanone.

This compound was previously described by Rao *et al.* [*Synth. Commun.* **2000**, *30*, 15, 2763-2768].

Example 25: 2-Chloro-1-phenyl-ethanone.

This compound was previously described by Rao *et al.* [*Synth. Commun.* **2000**, *30*, 15, 2763-2768].

Example 26: 2-Bromo-1-(2, 4, 6- tribromo-phenyl)-ethanone.

General procedure described for compounds **1** and **2** starting from 1,3,5-tribromobenzene and bromoacetyl bromide. Purified by column chromatography column (hexane:ethyl acetate 6:1), yield 45% m.p.: 86-87 °C, ¹H-NMR (CDCl₃): δ 7.7 (s, 2H, Ar), 4.44 (s, 2H, CH₂); ¹³C-NMR (CDCl₃): δ 193.4 (CO), 139.4 (C-CO), 134.5 (CH), 124.7 (C-Br), 119.4 (C-Br), 34.6 (CH₂); M/z (EI): 440, 438, 436, 434, 432 (M⁺, 1, 3, 5, 3, 1 %), 345, 343, 341, 339 (M-CH₂Br, 35, 96, 100, 41 %); HPLC: Column μ Bondapack C18, 5 μm, 300 A, (300 X 3.9 mm), Purity 98 %, r.t.= 3.40 min, acetonitrile / H₂O (0.05 % H₃PO₄ + 0.04 % Et₃N) 50/50.

Example 27: 2-Bromo-1-(3, 4- dibromo-phenyl)-ethanone.

General procedure described for compounds **1** and **2** starting from 1,2-dibromobenzene and bromoacetyl bromide. Purified by column chromatography column (hexane:ethyl acetate 6:1), yield 13% m.p.: 60-61 °C, ¹H-NMR (CDCl₃): δ 8.2 (s, 1H, Ar), 7.8 (d, 2H, Ar), 4.4 (s, 2H, CH₂) ; ¹³C-NMR (CDCl₃): δ 189.7 (CO), 134.6 (CH), 134.4 (CH), 134.3 (C-CO), 132.0 (C-Br), 128.8(CH), 126.2 (C-Br), 30.4 (CH₂); M/z (EI): 360, 358, 356, 354 (M⁺, 5, 14, 14, 5 %), 265, 263, 261 (M-CH₂Br, 62, 100, 65 %); HPLC: Column μ Bondapack C18, 5 μm, 300 A, (300 X 3.9 mm),

Purity 98 %, r.t.= 8.73 min, acetonitrile / H₂O (0.05 % H₃PO₄ + 0.04 % Et₃N) 50/50.

Example 28: 2-Bromo-1-(4-bromo-phenyl)-ethanone.

This compound was previously described by Huff *et al* [*Heterocycles*. **1997**, *45*, 7, 1363-1384].

Example 29: 2-Bromo-1-(4-chloro-phenyl)-ethanone.

This compound was previously described by Collet *et al* [*Bull. Soc. Chim. Fr.* **1899**, *21*, 67].

Example 30: 2-Bromo-1-phenyl-ethanone.

This compound was previously described by Collet *et al* [*Bull. Soc. Chim. Fr.* **1897**, *76*].

Example 31: 2-Bromo-1-p-tolyl-ethanone.

This compound was previously described by Huff *et al* [*Heterocycles*. **1997**, *45*, 7, 1363-1384].

Example 32: 2-Bromo-1-(4-methoxy-phenyl)-ethanone.

This compound was previously described by Kunckell *et al* [*Chem. Ber.* **1898**, *31*, 173]

Example 33: 1-Biphenyl-4-yl-2-bromo-ethanone.

This compound was previously described by Barfknecht *et al* [*J. Med. Chem.* **1975**, *18*, 1161-1164].

Example 34: 2-Bromo-2-chloro-1-(4-chloro-phenyl)-ethanone.

This compound was previously described by Otto *et al* [*Rocz. Chem.* **1973**, *47*, 967-969].

Example 35: 2-Bromo-2-chloro-1-phenyl-ethanone.

This compound was previously described by Barluenga *et al*. [*J. Chem. Soc. Perkin Trans. 1* **1991**, *2*, 297-300].

Example 36: 2,2-Dibromo-1-phenyl-ethanone.

This compound was previously described by Magen *et al*. [*Tetrahedron Lett.* **1984**, *25*, 31, 3369-3372].

Example 37: 2,2-Dibromo-1-(4-bromo-phenyl)-ethanone.

This compound was previously described by Klingenberg *et al*. [*Org. Synth. Coll. Vol. IV* **1963**, 110].

Example 38: 4-(2-Bromoacetyl)-benzonitrile.

This compound was previously described by Ogata, M *et al*. [*J. Med. Chem.* **1987**, *30*, 8, 1497-1502].

Example 39: 4-(2,2-Dibromo-acetyl)-benzonitrile.

This compound was previously described by Izawa *et al.* [*Bull. Chem. Soc. Jpn*, **1983**, 56, 5, 1490-1496].

Example 40: 2-Bromo-1-(4-trifluoromethyl-phenyl)-ethanone.

This compound was previously described by Schroeder *et al.* [*J. Med. Chem.*, **2001**, 44, 20, 3231-3243].

Example 41: 2,2-Dibromo-1-(4-trifluoromethyl-phenyl)-ethanone.

This compound was synthesised by the general procedure represented in Scheme 2, a stirred solution of 1-(4-trifluoromethyl-phenyl)-ethanone (1g, 5.3 mmol) and acetic acid (50 ml) was refluxed 1h, then bromine (0.35 ml, 6.9 mmol) was added dropwise and the mixture refluxed 3h. After cooling at room temperature, water (50 ml) was added and the mixture extracted with CH₂Cl₂ (50 ml), the organic layer was washed with water (50 ml), a solution of NaHCO₃ saturated (50 ml) and finally with NaCl solution (50 ml), the organic layer was dried over sodium sulphate and the solvent evaporated under reduced pressure. The resulting residue was purified by column chromatography, using a mixture of ethyl acetate:hexane (1:8) as eluent giving two compounds, the titled compound **41** as a yellow solid (45%) m.p.: 40-41° C, ¹H-NMR (CDCl₃): δ 8.2 (d, *J*= 8.3 Hz, 2H, Ar), 7.8 (d, *J*= 8.3 Hz, 2H, Ar), 6.6 (s, 1H, CH); ¹³C-NMR (CDCl₃): δ 184.1 (CO), 134.7 (q, *J*=272.9 Hz, C-CF₃), 132.7 (C-CO), 129.2 (CH), 124.8 (CH), 119.5 (q, *J*= 33.09, CF₃), 38.2 (CH); M/z (EI): 348, 346, 344 (M⁺, 1, 6, 1 %), 173 (M-CHBr₂, 100 %); HPLC: Column μ Bondapack C18, 5 μm, 300 A, (300 X 3.9 mm), Purity 97 %, r.t.= 9.96 min, acetonitrile / H₂O (0.05 % H₃PO₄ + 0.04 % Et₃N) 50/50. The second compound was identified as 2-bromo-1-(4-trifluoromethyl-phenyl)-ethanone (0,6%), described as the example **40**.

Example 42: 2-Bromo-1-(4-morpholin-4-yl-phenyl)-ethanone.

This compound was previously described by Diwu *et al.* [*Tetrahedron Lett.*, **1998**, *39*, 28, 4987-4990].

Example 43: 3-(2-Bromo-acetyl)-benzonitrile.

This compound was previously described by Tanaka *et al.* [*J. Med. Chem.*, **1998**, *41*, 13, 2390-2410].

Example 44: 3-(2,2-Dibromo-acetyl)-benzonitrile.

This compound was previously described by Watson *et al.* [*Bioorg. Med. Chem.*, **1998**, *6*, 6, 721-734].

Example 45: 2,2-Dibromo-1-(4-iodo-phenyl)-ethanone.

Procedure described in example 41 starting from 4-iodoacetophenone. The resulting residue was purified by column chromatography, using a mixture of hexane:ethyl acetate (6:1) as eluent. Yield 48%, colorless solid m.p.: 77-78 °C, ¹H-NMR (CDCl₃): δ 7.8 (d, J = 4.2 Hz, 2H, Ar), 7.7 (d, J=4.2 Hz, 2H, Ar), 6.3 (s, 1H, CH); ¹³C-NMR (CDCl₃): δ 185.8 (CO), 138.6 (CH), 131.3 (CH), 130.4 (C-CO), 103.4 (C-I), 39.6 (CH); M/z (EI): 406, 404, 402 (M⁺, 9, 17, 9 %), 231, (M-CHBr₂, 100 %); HPLC: Column Symmetry C18, 5 μm, 300 A, (150 X 3.9 mm), Purity 94 %, r.t.= 4.51 min, Conditions Acetonitrile / H₂O (0.05 % H₃PO₄ + 0.04 % Et₃N) 50/50.

Example 46: 2-Bromo-1-(4-nitro-phenyl)-ethanone.

This compound was previously described by Wan *et al* [J. Org. Chem., 1989, 54, 18, 4473-4474].

Example 47: 1-(4-Amino-3,5-dibromo-phenyl)-2-bromo-ethanone.

Procedure described in example 41 starting from *p*-aminoacetophenone and using chloroform as solvent. The final residue was purified by column chromatography, using a mixture of hexane:ethyl acetate (2:1) as eluent. Yield 58% m.p.: 146-147°C (ethanol), ¹H-NMR (CDCl₃): δ 8.0 (s, 2H, Ar), 5.1 (s, 2H, NH₂), 4.2 (s, 2H, CH₂); ¹³C-NMR (CDCl₃): δ 187.5 (CO), 147.3 (C-NH₂), 132.7 (CH), 123.3 (C-CO), 106.2 (C-Br), 38.3 (CH₂); M/z (EI): 375, 373, 371, 369 (M⁺, 10, 31, 31, 10 %), 280, 278, 276 (M-CH₂Br, 64, 100, 67 %); HPLC: Column Symmetry C18, 5 μm, 300 A, (150 X 3.9 mm), Purity 96 %, r.t.= 9.98 min, acetonitrile / H₂O (0.05 % H₃PO₄ + 0.04 % Et₃N) 50/50.

Example 48: 2-Iodo-1-(4-bromo-phenyl)-ethanone.

This compound was previously described by Shaw *et al.* [J. Amer. Chem. Soc, 1959, 81, 2532-2537].

Examples: Biological activity as enzymatic inhibitors of the compounds of the invention

1. Inhibition of GSK-3.- The GSK-3 inhibitory activity of the compound mentioned in this invention was measured by using a previously described method [Woodget, J.R.; Anal. Biochem. 1989, 180, 237-241]. This method consists of the incubation of commercially available GSK-3 with a phosphate source and a GSK-3 substrate in the presence and

absence of the corresponding compound to be tested, and the measurement of the GSK-3 activity in both mixtures.

In particular, the enzyme was incubated at 37°C for a 20 minutes period in buffer [tris pH = 7.5 (50 mM), EDTA (1 mM), EGTA (1 mM), DTT (1 mM) and MgCl₂ (10 mM)] supplemented by the synthetic peptide GS 1 (15 µM final concentration) as substrate, ATP (15 µM), [γ -³²P]ATP (0.2 µCi) and different concentrations of the product to be tested. After that, aliquots of the reaction mixtures are added on phosphocellulose p81 papers. These papers are washed three times with phosphoric acid 1% and the radioactivity incorporated to the GS 1 peptide is measured in a liquid scintillation counter.

Table 2 shows the data of GSK-3 inhibition, which is the object of this invention, of some representative compounds. The examples presented are explanatory and must be regarded as non-limitative in respect of the scope of protection. The numbers given with the different substituents represents the position of the substituent in the corresponding ring, in accordance with the IUPAC nomenclature rules. The GSK-3 inhibition data given as the inhibitory concentration 50, IC₅₀, defined as the concentration of the compound that inhibits the enzyme at 50%.

Tabla 2

comp.	-X-	COCY ¹ Y ² Y ³	R ¹	R ²	R ³	IC ₅₀ (µM)
1	-S-	3-COCH ₂ Cl	2-Br	4-Cl	5-Cl	2
2	-S-	2-COCH ₂ Cl	4-Cl	5-Cl	H	2.5
3	-S-	2-COCH ₂ Cl	4-Br	H	H	3
4	-S-	3-COCH ₂ Cl	4-Cl	H	H	25
5	-S-	3-COCH ₂ Cl	2-Br	4-Br	5-Br	1
6	-S-	3-COCH ₂ Cl	2-Cl	5-Cl	H	5

7	-S-	2-COCH ₂ Cl	5-Cl	H	H	10
8	-S-	2-COCH ₂ Cl	5-Br	H	H	10
9	-S-	2-COCH ₂ Cl	4-COCH ₂ Cl	H	H	1.5
10	-S-	2-COCH ₂ Cl	H	H	H	50
11	-S-	2-COCH ₂ Cl	4-COCH ₂ Cl	5-CH ₃	H	5
12	-S-	2-COCH ₂ Cl	5-CH ₃	H	H	100
13	-S-	3-COCH ₂ Cl	2-CH ₃	5-CH ₃	H	100
14	-S-	2-COCH ₂ Cl	4-Br	5-Br	H	1
15	-S-	2-COCH ₂ Cl	3-Br	4-Br	H	0.5
16	-S-	2-COCH ₂ Cl	3-CH ₃	4-COCH ₂ Cl	H	2.5
17	-S-	2-COCH ₂ Cl	4-CH ₃	H	H	100
18	-S-	2-COCH ₂ Cl	3-CH ₃	H	H	75
19	-S-	2-COCH ₂ Cl	5-COCH ₃	H	H	50
20	-S-	2-COCH ₂ Cl	4-COCH ₃	H	H	8
21	-S-	2-COCH ₂ Br	3-Br	4-Br	H	1
22	-S-	2-COCH ₂ Br	4-Br	5-Br	H	1
23	-S-	2-COCH ₂ Br	5-Br	H	H	1
24	-CH=CH-	COCH ₂ Cl	4-Cl	H	H	2.5
25	-CH=CH-	COCH ₂ Cl	H	H	H	50
26	-CH=CH-	COCH ₂ Br	2-Br	4-Br	6-Br	25
27	-CH=CH-	COCH ₂ Br	3-Br	4-Br	H	0.75
28	-CH=CH-	COCH ₂ Br	4-Br	H	H	0.5
29	-CH=CH-	COCH ₂ Br	4-Cl	H	H	1
30	-CH=CH-	COCH ₂ Br	H	H	H	5
31	-CH=CH-	COCH ₂ Br	4-CH ₃	H	H	2.5
32	-CH=CH-	COCH ₂ Br	4-OCH ₃	H	H	1
33	-CH=CH-	COCH ₂ Br	4-Ph	H	H	2.5

34	-CH=CH-	COCHBrCl	4-Cl	H	H	7.5
35	-CH=CH-	COCHBrCl	H	H	H	5
36	-CH=CH-	COCHBr ₂	H	H	H	2.5
37	-CH=CH-	COCHBr ₂	4-Br	H	H	0.75
38	-CH=CH-	COCH ₂ Br	4-CN	H	H	1.5
39	-CH=CH-	COCHBr ₂	4-CN	H	H	1.5
40	-CH=CH-	COCH ₂ Br	4-CF ₃	H	H	5
41	-CH=CH-	COCHBr ₂	4-CF ₃	H	H	5
42	-CH=CH-	COCH ₂ Br	4-Morpholine	H	H	6
43	-CH=CH-	COCH ₂ Br	3-CN	H	H	1
44	-CH=CH-	COCHBr ₂	3-CN	H	H	1
45	-CH=CH-	COCHBr ₂	4-I	H	H	2
46	-CH=CH-	COCH ₂ Br	4-NO ₂	H	H	2
47	-CH=CH-	COCH ₂ Br	3-Br	4-NH ₂	5-Br	3
48	-CH=CH-	COCH ₂ I	4-Br	H	H	3

2. In vitro effects of some compounds on tau phosphorylation in cultured neurones.

Primary cultured cerebellar neurones were obtained from 7-days old rat pups, following the procedure described by Levy *et al.* [Brain Res 1984, 290, 77-86]. Experiments were performed at 40-48 hours in vitro. Each compound was added at increasing concentrations following the range described in Table 3.

Cells were harvested after 16 hours of treatment and homogenised in a buffer containing 20 mM Hepes, pH 7.4; 100 mM NaCl; 100 mM NaF; 1mM sodium *ortho*-vanadate; 5 mM EDTA; and protease inhibitors Complete™.

Tau-1 antibody was used to monitor the tau phosphorylation changes because it is sensitive to dephosphorylation. In addition antibody 7.51 was used to detect the total amount of tau in our cultured neurones. The detection was realised in Western blots and the data quantified using an imaging densitometer (GS-710 model, BioRad)

Table 3 shows the data of Tau phosphorylation inhibition in neurones measured by Tau-1 immunoreactivity obtained from two representative compounds of this invention. The examples presented are for the purposes of explanation and are non-limitative of the scope of protection. The numbers given with the different substituents represents the position of the substituent in the corresponding ring, in accordance with the IUPAC nomenclature rules.


The IC₅₀, in this case, is defined as the concentration of the compound that produce the inhibition of tau 1-immunoreactivity in this specific epitope at a 50%

Table 3

-X-	CO-CY ¹ Y ² Y ³	R ¹	R ²	R ³	IC ₅₀ (μM)
-S-	3-CO-CH ₂ Cl	2-Br	4-Br	5-Br	30
-S-	3-CO-CH ₂ Cl	2-Br	4-Cl	5-Cl	30

CLAIMS

1. The use of a compound of formula I:



[wherein:

X represents -CH=CH-, -CH=CR-, -CR=CR-, -CO-, -O-, -NH-, -NR-, -S-, -SO-, -SO₂-, -CH=N-, -CR=N-, -CH=N(O)-, -CR=N(O)- or any other atom or group of atoms capable of forming a S- or 6-membered heterocyclic ring;

Y¹, Y² and Y³ independently represent hydrogen or halogen;

R¹, R² and R³ are independently represent hydrogen, halogen, hydrocarbyl (-R), hydroxyl (-OH), hydrocarbyloxy (-O-R), mercapto (-SH), hydrocarbylthio (-S-R), hydrocarbylsulfinyl (-SO-R), hydrocarbylsulfonyl (-SO₂-R), nitro (-NO₂), amino (-NH₂), hydrocarbylamino (-NHR), bis(hydrocarbyl)amino (-NR₂), hydrocarbylcarbonylamino (-NH-CO-R), cyano (-CN), carbamoyl (-CONH₂), hydrocarbylcarbamoyl (-CONHR), bis(hydrocarbyl)carbamoyl (-CONR₂), carboxyl (-CO₂H), hydrocarbyloxycarbonyl (-CO₂R), formyl (-CHO), hydrocarbylcarbonyl (-COR), hydrocarbylcarbonyloxy (-OCOR), optionally substituted heteroaryl or optionally substituted heterocyclic; and

the hydrocarbyl group R is a straight or branched chain hydrocarbyl group selected from alkyl, alkenyl, alkynyl, aryl, aralkyl, aralkenyl and aralkynyl, which may optionally be substituted by one or more substituents, selected from those defined above in relation to R¹, R² and R³]; in the manufacture of a medicament for the treatment of a disease mediated by the activation of GSK-3.

2. A use according to claim 1, wherein X is selected from -CH=CH-, -CH=CR-, -CR=CR-, -CH=N-, -CR=N-, -O-, -NH-, -NR-, and -S- (the group R representing C₁₋₆ alkyl or C₆₋₁₀ aryl).
3. A use according to claim 1, wherein X is selected from -CH=CH-, -CH=CR-, -CR=CR-, --O- and -S- (the group R representing C₁₋₆ alkyl).
4. A use according to claim 1, wherein X is selected from -CH=CH- and -S-.
5. A use according to any one of claims 1 to 4, wherein one or two of Y¹, Y² and Y³ are halogen, and the other two or one are hydrogen.
6. A use according to any one of claims 1 to 4, wherein one of Y¹, Y² and Y³ is halogen, and the other two are hydrogen.
7. A use according to any one of claims 1 to 4, wherein one of Y¹, Y² and Y³ is chlorine, bromine or iodine, and the other two are hydrogen.
8. A use according to any one of claims 1 to 7, wherein R¹, R² and R³ are independently selected from hydrogen, halogen, C₁₋₆ alkyl (which may be optionally substituted with one or more substituents selected from halogen, hydroxy, C₁₋₆ alkoxy and cyano), C₆₋₁₀ aryl, optionally substituted C₇₋₁₆ aralkyl, hydroxy, C₁₋₆ alkoxy, C₆₋₁₀ aryloxy, C₇₋₁₆ aralkyloxy, C₁₋₆ alkylthio, C₆₋₁₀ arylthio, C₇₋₁₆ aralkylthio, C₁₋₆ alkylsulfinyl, C₆₋₁₀ arylsulfinyl, C₇₋₁₆ aralkylsulfinyl, C₁₋₆ alkylsulfonyl, C₆₋₁₀ arylsulfonyl, C₇₋₁₆ aralkylsulfonyl, cyano, carboxyl, C₁₋₆ alkyloxycarbonyl, C₇₋₁₁ aryloxycarbonyl, C₈₋₁₆

aralkyloxycarbonyl, heteroaryl and C₁-30 aliphatic acyl (which may be optionally substituted with a halogen atom).

9. A use according to any one of claims 1 to 7, wherein R¹, R² and R³ are independently selected from hydrogen, halogen, C₁-6 alkyl (which may be optionally substituted with one or more substituents selected from halogen, hydroxy and C₁-6 alkoxy), C₁-6 alkoxy C₆-10 aryl, heteroaryl, nitro, amino and C₁-20 aliphatic acyl (which may be optionally substituted with one or more substituents selected from halogen, hydroxy and C₁-6 alkoxy and cyano).
10. A use according to any one of claims 1 to 7, wherein R¹, R² and R³ are independently selected from hydrogen, halogen, C₁-4 alkyl (which may be optionally substituted with one or more halogen atoms), C₁-4 alkoxy, C₆-10 aryl, heteroaryl, nitro, amino and C₂-6 aliphatic acyl (which may be optionally substituted with one or more halogen atoms), provided that at least one of R¹, R² and R³ are other than hydrogen.
11. A use according to any one of claims 1 to 7, wherein R¹, R² and R³ are independently selected from hydrogen, chorine, bromine, methyl, ethyl, methoxy, ethoxy, acetyl, chloroacetyl, phenyl, morpholino, nitro, amino, and bromoacetyl, provided that at least one of R¹, R² and R³ is other than hydrogen.
12. A use according to any one of claims 1 to 7, wherein R¹, R² and R³ are independently selected from hydrogen, chloro, bromo, iodo, methyl, methoxy, acetyl, phenyl, morpholino, nitro, amino, and chloroacetyl, provided that at least one of R¹, R² and R³ is other than hydrogen.

13. A use according to any one of claims 1 to 12, selected from the following table:

comp.	-X-	COCY ¹ Y ² Y ³	R ¹	R ²	R ³
1	-S-	3-COCH ₂ Cl	2-Br	4-Cl	5-Cl
2	-S-	2-COCH ₂ Cl	4-Cl	5-Cl	H
3	-S-	2-COCH ₂ Cl	4-Br	H	H
4	-S-	3-COCH ₂ Cl	4-Cl	H	H
5	-S-	3-COCH ₂ Cl	2-Br	4-Br	5-Br
6	-S-	3-COCH ₂ Cl	2-Cl	5-Cl	H
7	-S-	2-COCH ₂ Cl	5-Cl	H	H
8	-S-	2-COCH ₂ Cl	5-Br	H	H
9	-S-	2-COCH ₂ Cl	4-COCH ₂ Cl	H	H
10	-S-	2-COCH ₂ Cl	H	H	H
11	-S-	2-COCH ₂ Cl	4-COCH ₂ Cl	5-CH ₃	H
12	-S-	2-COCH ₂ Cl	5-CH ₃	H	H
13	-S-	3-COCH ₂ Cl	2-CH ₃	5-CH ₃	H
14	-S-	2-COCH ₂ Cl	4-Br	5-Br	H
15	-S-	2-COCH ₂ Cl	3-Br	4-Br	H
16	-S-	2-COCH ₂ Cl	3-CH ₃	4- COCH ₂ Cl	H
17	-S-	2-COCH ₂ Cl	4-CH ₃	H	H
18	-S-	2-COCH ₂ Cl	3-CH ₃	H	H
19	-S-	2-COCH ₂ Cl	5-COCH ₃	H	H
20	-S-	2-COCH ₂ Cl	4-COCH ₃	H	H
21	-S-	2- COCH ₂ Br	3-Br	4-Br	H
22	-S-	2- COCH ₂ Br	4-Br	5-Br	H
23	-S-	2-	5-Br	H	H

		COCH ₂ Br			
24	-CH=CH-	COCH ₂ Cl	4-Cl	H	H
25	-CH=CH-	COCH ₂ Cl	H	H	H
26	-CH=CH-	COCH ₂ Br	2-Br	4-Br	6-Br
27	-CH=CH-	COCH ₂ Br	3-Br	4-Br	H
28	-CH=CH-	COCH ₂ Br	4-Br	H	H
29	-CH=CH-	COCH ₂ Br	4-Cl	H	H
30	-CH=CH-	COCH ₂ Br	H	H	H
31	-CH=CH-	COCH ₂ Br	4-CH ₃	H	H
32	-CH=CH-	COCH ₂ Br	4-OCH ₃	H	H
33	-CH=CH-	COCH ₂ Br	4-Ph	H	H
34	-CH=CH-	COCHBrCl	4-Cl	H	H
35	-CH=CH-	COCHBrCl	H	H	H
36	-CH=CH-	COCHBr ₂	H	H	H
37	-CH=CH-	COCHBr ₂	4-Br	H	H
38	-CH=CH-	COCH ₂ Br	4-CN	H	H
39	-CH=CH-	COCHBr ₂	4-CN	H	H
40	-CH=CH-	COCH ₂ Br	4-CF ₃	H	H
41	-CH=CH-	COCHBr ₂	4-CF ₃	H	H
42	-CH=CH-	COCH ₂ Br	4- Morpholine	H	H
43	-CH=CH-	COCH ₂ Br	3-CN	H	H
44	-CH=CH-	COCHBr ₂	3-CN	H	H
45	-CH=CH-	COCHBr ₂	4-I	H	H
46	-CH=CH-	COCH ₂ Br	4-NO ₂	H	H
47	-CH=CH-	COCH ₂ Br	3-Br	4-NH ₂	5-Br
48	-CH=CH-	COCH ₂ I	4-Br	H	H


14. A use according to any preceding claim, wherein the disease is Alzheimer's disease.

15. A use according to any of claims 1 to 13, wherein the disease is non-dependent insulin diabetes mellitus.

16. A use according to any one of claims 1 to 13 in the manufacture of a medicament for the treatment of a hyperproliferative disease.

17. A use according to claim 16, wherein the hyperproliferative disease is selected from cancer, displasias and metaplasia of different tissues, psoriasis, arteriosclerosis and restenosis.

18. A compound of formula I:



wherein:

X represents -CH=CH-, -CH=CR-, -CR=CR-, -CO-, -O-, -NH-, -NR-, -S-, -SO-, -SO₂-, -CH=N-, -CR=N-, -CH=N(O)-, -CR=N(O)- or any other atom or group of atoms capable of forming a S- or 6-membered heterocyclic ring;

Y¹, Y² and Y³ independently represent hydrogen or halogen;

R¹, R² and R³ are independently represent hydrogen, halogen, hydrocarbyl (-R), hydroxyl (-OH), hydrocarbyloxy (-O-R), mercapto (-SH), hydrocarbylthio (-S-R), hydrocarbylsulfinyl (-SO-R), hydrocarbylsulfonyl (-SO₂-R), nitro (-NO₂), amino (-NH₂), hydrocarbylamino (-NHR), bis(hydrocarbyl)amino (-NR₂), hydrocarbylcarbonylamino (-NH-CO-R), cyano (-CN), carbamoyl (-CONH₂), hydrocarbylcarbamoyl (-CONHR), bis(hydrocarbyl)carbamoyl (-CONR₂), carboxyl (-CO₂H), hydrocarbyloxycarbonyl (-CO₂R), formyl (-CHO), hydrocarbylcarbonyl (-COR), hydrocarbylcarbonyloxy (-OCOR),

optionally substituted heteroaryl or optionally substituted heterocyclic; and

the hydrocarbyl group R is a straight or branched chain hydrocarbyl group selected from alkyl, alkenyl, alkynyl, aryl, aralkyl, aralkenyl and aralkynyl, which may optionally be substituted by one or more substituents, selected from those defined above in relation to R¹, R² and R³.

19. A pharmaceutical preparation containing as active ingredient a compound according to claim 18.

20. A compound according to claim 18 for use as a medicament.

21. A method of treatment of a disease mediated by the activation of GSK-3, the method comprising administering an effective amount of a compound according to claim 18.

INTERNATIONAL SEARCH REPORT

PCT/GB 02/05768

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 A61K31/38 C07D333/22 C07C49/537 A61P25/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 IPC 7 A61K C07D C07C A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 02 092086 A (HOFFMANN LA ROCHE) 21 November 2002 (2002-11-21) page 1, 1st paragraph; RN-CAPLUS: 435273-49-7 claims ---	18
P, X	WO 02 100826 A (KASIBHATLA SHAILAJA ;CAI SUI XIONG (US); CYTOVIA INC (US); DREWE J) 19 December 2002 (2002-12-19) RN-CAPLUS: 256486-71-2 ---	18
X	WO 00 75094 A (JONISHI HISAYOSHI ;KOTANI AKIHIRO (JP); ISHIHARA SANGYO KAISHA (JP) 14 December 2000 (2000-12-14) example 1, last two lines ---	18 -/-

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
19 February 2003	27/02/2003
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl Fax: (+31-70) 340-3016	Authorized officer Schmid, A

INTERNATIONAL SEARCH REPORT

PCT/GB 02/05768

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 01 02387 A (OHNE KAZUHIKO ; OHKAWA TAKEHIKO (JP); SATO KENTARO (JP); SHIMA ICHI) 11 January 2001 (2001-01-11) RN-CAPLUS: 210832-85-2 and 319458-71-4 ---	18
X	EP 1 080 641 A (NALCO CHEMICAL CO) 7 March 2001 (2001-03-07) page 4, line 30 -page 4, line 31 ---	18
X	US 6 156 776 A (RIVIELLO CHRISTOPHER MARK ET AL) 5 December 2000 (2000-12-05) RN-CAPLUS: 311313-19-6 ---	18
A	US 2001/016595 A1 (GAUTHIER JACQUES YVES ET AL) 23 August 2001 (2001-08-23) page 1, '0011! and '0012!; table 2, thiophene derivatives claims; examples 1-6 ---	1-21
A	US 5 109 017 A (SCHMIESING RICHARD J ET AL) 28 April 1992 (1992-04-28) column 1, line 16 -column 1, line 24; claims; examples 1-5 -----	1-21

INTERNATIONAL SEARCH REPORT

International Application No. PCT/GB 02 05768

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 18-20 (partly)

The initial phase of the search revealed a very large number of documents relevant to the issue of novelty. So many documents were retrieved that it is impossible to determine which parts of the claims may be said to define subject-matter for which protection might legitimately be sought (Article 6 PCT). For these reasons, a meaningful search over the whole breadth of the claim(s) is impossible. Consequently, the search has been restricted to the compounds of the present examples and closely related ones. Nevertheless the search still revealed a very large number of documents relevant to the issue of novelty. Only a small number of representative documents has been cited to show that at least the subject-matter of present claim 18 is not novel.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

PCT/GB 02/05768

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Although claim 21 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: 18-20 (partly) because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of Invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

PCT/GB 02/05768

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
WO 02092086	A	21-11-2002	WO US	02092086 A1 2002188128 A1		21-11-2002 12-12-2002
WO 02100826	A	19-12-2002	WO	02100826 A2		19-12-2002
WO 0075094	A	14-12-2000	WO JP	0075094 A2 2001048825 A		14-12-2000 20-02-2001
WO 0102387	A	11-01-2001	EP WO	1196407 A1 0102387 A1		17-04-2002 11-01-2001
EP 1080641	A	07-03-2001	US AU BR EP NO WO	6419879 B1 6395400 A 0013130 A 1080641 A2 20004055 A 0111954 A2		16-07-2002 13-03-2001 17-12-2002 07-03-2001 13-02-2001 22-02-2001
US 6156776	A	05-12-2000	FR US US US US US	2816617 A1 2001000178 A1 2002002193 A1 6277873 B1 2001000512 A1 2001000177 A1		17-05-2002 05-04-2001 03-01-2002 21-08-2001 26-04-2001 05-04-2001
US 2001016595	A1	23-08-2001	US AU AU EP WO IL JP US ZA AT AU AU AU AU AU AU BG BG BG BG BR BR CA CA CA CA CA WO WO CN CN CN CN CZ DE DK	5474995 A 715676 B2 3613995 A 0785778 A1 9611676 A1 115505 A 10507445 T 5840746 A 9508558 A 165825 T 1269495 A 1913297 A 691119 B2 6197096 A 6967494 A 63161 B1 100247 A 63082 B1 100350 A 9406979 A 9408478 A 2163888 A1 2176973 A1 2176974 A1 2180651 A1 9500501 A2 9518799 A1 1295065 A 1125944 A , B 1143365 A 9503146 A3 69410092 D1 705254 T3		12-12-1995 10-02-2000 06-05-1996 30-07-1997 25-04-1996 31-12-1999 21-07-1998 24-11-1998 04-04-1997 15-05-1998 01-08-1995 14-08-1997 07-05-1998 31-10-1996 17-01-1995 31-05-2001 28-06-1996 30-03-2001 31-12-1996 05-03-1996 26-08-1997 05-01-1995 25-12-1994 25-12-1994 13-07-1995 05-01-1995 13-07-1995 16-05-2001 03-07-1996 19-02-1997 15-05-1996 10-06-1998 25-01-1999

INTERNATIONAL SEARCH REPORT

PCT/GB 02/05768

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
US 2001016595	A1	EP	0705254 A1	10-04-1996
		EP	0739340 A1	30-10-1996
		EP	0754687 A1	22-01-1997
		EP	0822190 A1	04-02-1998
		EP	0980866 A2	23-02-2000
		ES	2115237 T3	16-06-1998
		FI	956119 A	19-12-1995
		FI	962800 A	06-09-1996
		FI	20012510 A	19-12-2001
		HK	1027474 A1	12-01-2001
		HR	940373 A1	31-12-1996
		HU	74070 A2	28-10-1996
		HU	74986 A2	28-03-1997
		IL	110031 A	31-01-2000
		IL	123002 A	30-04-2001
		JP	2977137 B2	10-11-1999
US 5109017	A	28-04-1992	AT	154349 T
			DE	69126537 D1
			DE	69126537 T2
			DK	557305 T3
			EP	0557305 A1
			ES	2103004 T3
			GR	3024553 T3
			HU	9500460 A3
			IE	913279 A1
			JP	3108433 B2
			JP	6501472 T
			PT	99050 A ,B
			WO	9205169 A1